- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00711191
A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas
A Phase 1 Dose Escalation Open Label Study Of CP-870,893 In Combination With Gemcitabine In Patients With Chemotherapy-Naïve Surgically Incurable Pancreatic Cancer
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
Indiana
-
Indianapolis, Indiana, Förenta staterna, 46202
- Pfizer Investigational Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19104
- Pfizer Investigational Site
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- 1st-line surgically incurable cancer of the pancreas
- ECOG(Eastern Cooperative Oncology Group) performance status 0-1
Exclusion Criteria:
- Previous systemic therapy for pancreas cancer
- History of cancer-associated blood clots
- History of autoimmune disease
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: singelarm
|
CP-870,893 intravenous administration [IV] on day 3 of 4-week cycles
gemcitabine 1000 mg/m^2 intravenous administration [IV] q week [wk]x3 of 4-week cycles
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Number of Participants With Dose Limiting Toxicities (DLTs)
Tidsram: Baseline up to Cycle 1 / Day 28
|
Any of the following during first cycle of treatment and attributable to CP-870893: afebrile Grade (Gr) 4 neutropenia (absolute neutrophil count [ANC] <500 cells/mm^3) ≥7 days or Gr 3 or 4 neutropenia associated with fever (1 oral temperature >38.5 degrees Celsius (C) or 3 oral temperatures >38.0 degrees C in a 24-hour period); Gr 4 thrombocytopenia or Gr 3 thrombocytopenia associated with bleeding; Gr 4 lymphopenia, if coupled with clinical consequence (such as, opportunistic infection) or any other Gr 3 hematological adverse events; ≥Gr 3 non-hematologic toxicities (except alopecia). |
Baseline up to Cycle 1 / Day 28
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Percentage of Participants With Objective Tumor Response According to Response Evaluation Criteria in Solid Tumors (RECIST)
Tidsram: At the end of every even-numbered cycle (cycle=28 days) up to a maximum of 12 cycles and 4 to 6 weeks following initial documentation of response
|
Number of participants with objective response based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST.
Confirmed CR defined as disappearance of all target lesions.
Confirmed PR defined as ≥30% decrease in sum of the longest dimensions (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST.
Confirmed responses are those that persist on repeat imaging study ≥4 weeks after initial documentation of response.
|
At the end of every even-numbered cycle (cycle=28 days) up to a maximum of 12 cycles and 4 to 6 weeks following initial documentation of response
|
Overall Survival (OS)
Tidsram: Baseline, assessed monthly until death or 7.5 months after last participant was enrolled (up to January 2011)
|
OS is time from baseline to death from any cause.
Participants last known to be alive were censored at the date of last contact.
|
Baseline, assessed monthly until death or 7.5 months after last participant was enrolled (up to January 2011)
|
Progression Free Survival (PFS)
Tidsram: Baseline, assessed monthly until death or 7.5 months after last participant was enrolled (up to January 2011)
|
PFS is time from baseline to first progression (Prog) or death from any cause.
Participants last known to be alive, had not started a new (non-protocol) cancer treatment, were Prog-free, and who had a baseline and ≥1 on-study disease assessment were censored at date of last objective disease assessment that verified lack of Prog.
Participants who were off treatment prior to Prog and who had no on-study disease assessment were also censored.
Prog: ≥20% increase in sum of longest dimension (LD) of target lesions from smallest sum LD recorded since treatment start or appearance of ≥1 new lesions.
|
Baseline, assessed monthly until death or 7.5 months after last participant was enrolled (up to January 2011)
|
Time to Progression
Tidsram: Monthly until death or 7.5 months after last participant was enrolled (up to January 2011)
|
Disease progression defined as ≥20% increase in sum LD of target lesions from smallest sum LD recorded since treatment start or appearance of ≥1 new lesions.
Criteria for progression also included unequivocal progression of existing nontarget lesions.
|
Monthly until death or 7.5 months after last participant was enrolled (up to January 2011)
|
Maximum Serum Concentration (Cmax)
Tidsram: Cycle 1 / Day 3 pre-dose, 5 minutes after End of Infusion (EOI), and 2, 6, and 24 hours after EOI and pre-dose on Day 3 of every subsequent cycle up to a maximum of 12 cycles
|
Cycle 1 / Day 3 pre-dose, 5 minutes after End of Infusion (EOI), and 2, 6, and 24 hours after EOI and pre-dose on Day 3 of every subsequent cycle up to a maximum of 12 cycles
|
|
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
Tidsram: Cycle 1 / Day 3 pre-dose, 5 minutes after EOI, and 2, 6, and 24 hours after EOI and pre-dose on Day 3 of every subsequent cycle up to a maximum of 12 cycles
|
Area under the serum concentration time-curve from time zero to the last measured concentration.
AUClast analyzed using a noncompartmental approach to estimate individual participant values.
|
Cycle 1 / Day 3 pre-dose, 5 minutes after EOI, and 2, 6, and 24 hours after EOI and pre-dose on Day 3 of every subsequent cycle up to a maximum of 12 cycles
|
Change (Pre-dose to Post-dose) in Plasma Cytokine Concentrations: Pre-dose Concentration (CYTO0), Maximum Concentration (CTYOMAX)
Tidsram: Cycle 1 / Day 1 prior to gemcitabine infusion (0 hour), 5 minutes after EOI and 2, 4, 6, and 24 hours after EOI; Cycle 1 / Day 3 prior to CP-970893 infusion (0 hour), 5 minutes after EOI, and 2, 4, 6, and 24 hours after EOI
|
An increase in values indicates greater cytokine release from cells targeted by the antibody and may be associated with an infusion reaction.
Change calculated as mean of pre-dose and maximum post-dose values.
|
Cycle 1 / Day 1 prior to gemcitabine infusion (0 hour), 5 minutes after EOI and 2, 4, 6, and 24 hours after EOI; Cycle 1 / Day 3 prior to CP-970893 infusion (0 hour), 5 minutes after EOI, and 2, 4, 6, and 24 hours after EOI
|
Change (Pre-dose to Post-dose) in Plasma Cytokine Concentrations: Time of Maximum Concentration (TCYTOMAX)
Tidsram: Cycle 1 / Day 1 prior to gemcitabine infusion (0 hour), 5 minutes after EOI and 2, 4, 6, and 24 hours after EOI; Cycle 1 / Day 3 prior to CP-970893 infusion (0 hour), 5 minutes after EOI, and 2, 4, 6, and 24 hours after EOI
|
An increase in values indicates greater cytokine release from cells targeted by the antibody and may be associated with an infusion reaction.
Change calculated as mean of pre-dose and maximum post-dose values.
|
Cycle 1 / Day 1 prior to gemcitabine infusion (0 hour), 5 minutes after EOI and 2, 4, 6, and 24 hours after EOI; Cycle 1 / Day 3 prior to CP-970893 infusion (0 hour), 5 minutes after EOI, and 2, 4, 6, and 24 hours after EOI
|
Total and Neutralizing Human Antihuman Antibody (HAHA) Titer
Tidsram: Prior to infusion of CP-870893 on Day 3 of every cycle up to a maximum of 12 cycles
|
HAHA assessed as an indicator of immunogenicity to CP-870893.
|
Prior to infusion of CP-870893 on Day 3 of every cycle up to a maximum of 12 cycles
|
Change (Pre-dose to Post-dose) in Bone Marrow Derived Cells (B Cell) Surface Markers: CD54, CD23, CD40, CD86, and Human Leukocyte Antigen (HLA-DR)
Tidsram: Cycle 1 / Day 1 and Cycle 1 / Day 8 prior to gemcitabine infusion and 6 and 24 hours after EOI; Cycle 1 / Day 3 prior to CP-870893 infusion and 6, 24, and 48 hours after EOI
|
Assess the ability of PF-870893 to activate B-cells and HLA-DR which are involved in the production of antibodies.
Change calculated as mean of pre-dose and post-dose values.
Positive values indicate greater presence of cells associated with antibody production.
|
Cycle 1 / Day 1 and Cycle 1 / Day 8 prior to gemcitabine infusion and 6 and 24 hours after EOI; Cycle 1 / Day 3 prior to CP-870893 infusion and 6, 24, and 48 hours after EOI
|
18-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) Imaging (MTD Expansion Cohort)
Tidsram: Baseline, Week 2, Week 8, and Single Time Point (STP) PET for all PET scans after Week 8
|
FDG PET assessment to characterize and monitor tumors before and after study treatment; measured as a standardized uptake value (SUV).
A reduction in SUV from baseline for at least 1 tumor may indicate a positive metabolic response to treatment.
|
Baseline, Week 2, Week 8, and Single Time Point (STP) PET for all PET scans after Week 8
|
Carbohydrate Antigen 19-9 (CA 19-9)
Tidsram: At the end of every even-numbered cycle (cycle=28 days) and 4 to 6 weeks following initial documentation of response
|
CA 19-9 or sialylated Lewis (a) antigen (a tumor marker).
Values higher than 37 units per milliliter (U/ml) considered abnormal; higher values usually indicate greater presence of disease.
|
At the end of every even-numbered cycle (cycle=28 days) and 4 to 6 weeks following initial documentation of response
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Recommended Phase 2 Dose (RP2D) of CP-870893 in Participants With Advanced Pancreas Cancer
Tidsram: Baseline up to time of determination of maximum tolerated dose (MTD)
|
Additional participants enrolled at MTD of CP-870893 to further characterize suitability for phase 2 testing.
RP2D confirmed if ≤ 3 our of 12 participants in expansion cohort experience DLT in cycle 1.
|
Baseline up to time of determination of maximum tolerated dose (MTD)
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Matsmältningssystemets sjukdomar
- Neoplasmer
- Neoplasmer efter plats
- Sjukdomar i det endokrina systemet
- Neoplasmer i matsmältningssystemet
- Neoplasmer i endokrina körtel
- Bukspottkörtelsjukdomar
- Pankreatiska neoplasmer
- Läkemedels fysiologiska effekter
- Immunologiska faktorer
- Antikroppar
- Antikroppar, monoklonala
Andra studie-ID-nummer
- A5021005
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Pankreatisk neoplasma
-
Tianjin Medical University Cancer Institute and...Har inte rekryterat ännuPDAC - Pancreatic Ductal Adenocarcinoma
-
Sun Yat-sen UniversityRekryteringPDAC - Pancreatic Ductal AdenocarcinomaKina
-
Azienda Ospedaliera Universitaria Integrata VeronaRekryteringPDAC - Pancreatic Ductal AdenocarcinomaItalien
-
Cedars-Sinai Medical CenterRekryteringPDAC - Pancreatic Ductal AdenocarcinomaFörenta staterna
-
Azienda Ospedaliera Universitaria Integrata VeronaRekryteringPDAC - Pancreatic Ductal AdenocarcinomaItalien
-
Radboud University Medical CenterDutch Cancer SocietyRekryteringPDAC - Pancreatic Ductal AdenocarcinomaNederländerna
-
Imperial College LondonThe Leeds Teaching Hospitals NHS Trust; Sheffield Teaching Hospitals NHS... och andra samarbetspartnersRekryteringBukspottskörtelcancer | PDAC - Pancreatic Ductal AdenocarcinomaStorbritannien
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)AvslutadMetastatisk malign neoplasm | Ooperbar malign neoplasm | Avancerad malign neoplasmFörenta staterna
-
Massachusetts General HospitalRekryteringMalign neoplasm | Benign neoplasmFörenta staterna
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, inte rekryterandeMetastatisk malign neoplasm | Avancerad malign neoplasm | Återkommande malign neoplasm | Refraktär malign neoplasm | Lokalt avancerad malign neoplasmFörenta staterna
Kliniska prövningar på monoclonal antibody
-
Université de SherbrookeAvslutadFör tidig födselKanada
-
The Second Affiliated Hospital of Chongqing Medical...RekryteringSARS-CoV-2 | FörebyggandeKina
-
MedMira Laboratories Inc.Avslutad
-
Centre hospitalier de l'Université de Montréal...Fonds de la Recherche en Santé du QuébecAvslutadAktiva eller ex-injektion droganvändare | Indikation på hepatit C-screeningKanada
-
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co...RekryteringAvancerade/metastatiska solida tumörerKina
-
University of SouthamptonWest Hertfordshire Hospitals NHS TrustAvslutad
-
National Cancer Institute (NCI)AvslutadHematopoetisk och lymfoid cellneoplasma | Malign fast neoplasma | Lunginflammation | Symtomatisk COVID-19-infektion Laboratorie-bekräftad | Svårt akut andnödsyndrom | PneumonitFörenta staterna
-
Unity Health TorontoCanadian Institutes of Health Research (CIHR)Aktiv, inte rekryterandeHIV-infektioner | HIV-testningKanada
-
Northwell HealthRegeneron PharmaceuticalsIndragenCovid-19 | OrgantransplantationFörenta staterna
-
Fujian Cancer HospitalRekryteringSteg IIIA Hepatocellulärt karcinomKina